Vita Life SciencesASX:VLS 94 FCF Yield % is 11.67 as of Jun. 25, 2026, which is 102% above its 10-year median of 5.79. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Vita Life Sciences ranks better than 89.95% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vita Life Sciences FCF Yield % Related Terms
Vita Life Sciences FCF Yield % Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences FCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a FCF Yield % of 11.67 as of Jun. 25, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vita Life Sciences and its competitors. This is 102% above median its historical median of 5.79. Over the past decade, Vita Life Sciences' FCF Yield % has ranged from 2.65 to 15.74. According to the industry distribution chart, Vita Life Sciences ranks #101 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 10%.
Is Vita Life Sciences' FCF Yield % too high?
Vita Life Sciences' current FCF Yield % of 11.67 is 102% above median its 10-year median of 5.79. Over the past 10 years, this metric has ranged from a low of 2.65 to a high of 15.74. The Drug Manufacturers industry median FCF Yield % is 0.67. Vita Life Sciences' value of 11.67 is 1641.8% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #101 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' FCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #101 out of 1005 companies for FCF Yield %. This places Vita Life Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median FCF Yield % is 0.67. Vita Life Sciences' value of 11.67 is 1641.8% above this benchmark. Historically, Vita Life Sciences' own FCF Yield % has ranged from 2.65 to 15.74 over the past decade. While the company's 10-year median is 5.79 vs. the industry median of 0.67, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current FCF Yield % of 11.67 is 1641.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current FCF Yield % is 11.67, which is 102% above median its own 10-year median of 5.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current FCF Yield % is 11.67, which is 102% above median its 10-year median of 5.79 and 1641.8% above the Drug Manufacturers industry median of 0.67. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current FCF Yield % is 11.67 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
FCF Yield %: 11.67 (102% above median its 10-year median of 5.79)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
Industry Position: 1641.8% above the Drug Manufacturers median (#101 of 1005)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
